- A high proportion of thyroid nodules that undergo fine-needle aspiration are classified as cytologically indeterminate
- Molecular testing offers a unique approach to improve risk stratification. This allows clinicians to assess indeterminate lesions and also prevents unnecessary surgical procedures
- Currently, 4 tests are commercially available, with ThyraMIR®/ThyGeNEXT® being two of the cheapest options
Outcomes of Molecular Testing in Cytologically Indeterminate Thyroid Nodules
Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.